Skip to main content

Research Repository

Advanced Search

Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system

Man, Kenneth K.C.; Coghill, David; Chan, Esther W.; Lau, Wallis C.Y.; Hollis, Chris; Liddle, Elizabeth; Banschewski, Tobias; McCarthy, Suzanne; Neuberg, Antje; Sayal, Kapil; Ip, Patrick; Wong, Ian C.K.

Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system Thumbnail


Authors

Kenneth K.C. Man

David Coghill

Esther W. Chan

Wallis C.Y. Lau

CHRIS HOLLIS chris.hollis@nottingham.ac.uk
Professor of Child and Adolescent Psychiatry and Digital Mental Health

Tobias Banschewski

Suzanne McCarthy

Antje Neuberg

KAPIL SAYAL kapil.sayal@nottingham.ac.uk
Professor of Child and Adolescent Psychiatry

Patrick Ip

Ian C.K. Wong



Abstract

Previous studies have suggested that risk of psychotic events may be increased in children exposed to methylphenidate (MPH). However, this risk has not been fully examined and the possibility of confounding factors has not been excluded. Patients aged 6-19 years who received at least one MPH prescription were identified using Hong Kong population-based electronic medical records on the Clinical Data Analysis & Reporting System (2001-2014). Using the self-controlled case series design, relative incidence of psychotic events was calculated comparing periods when patients were exposed to MPH with non-exposed periods. Of 20 586 patients prescribed MPH, 103 had an incident psychotic event; 72 (69.9%) were male and 31 (30.1%) female. The mean age at commencement of observation was 6.95 years and the mean follow-up per participant was 10.16 years. On average, each participant was exposed to MPH for 2.17 years. The overall incidence of psychotic events during the MPH exposure period was 6.14 per 10 000 patient-years. No increased risk was found during MPH exposed compared to non-exposed periods (incidence rate ratio (IRR) 1.02 (0.53-1.97)). However, an increased risk was found during the pre-exposure period (IRR 4.64 (2.17-9.92)). Results were consistent across all sensitivity analyses. This study does not support the hypothesis that MPH increases risk of incident psychotic events. It does indicate an increased risk of psychotic events prior to the first prescription of MPH, which may be due to an association between psychotic events and the behavioural and attentional symptoms that led to psychiatric assessment and initiation of MPH treatment.

Citation

Man, K. K., Coghill, D., Chan, E. W., Lau, W. C., Hollis, C., Liddle, E., …Wong, I. C. (in press). Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Translational Psychiatry, 6, Article e956. https://doi.org/10.1038/tp.2016.216

Journal Article Type Article
Acceptance Date Aug 24, 2016
Online Publication Date Nov 15, 2016
Deposit Date Nov 25, 2016
Publicly Available Date Nov 25, 2016
Journal Translational Psychiatry
Electronic ISSN 2158-3188
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 6
Article Number e956
DOI https://doi.org/10.1038/tp.2016.216
Keywords Attention-Deficit/Hyperactivity Disorder; Psychotic disorder; Hallucinations; Methylphenidate; Self-Controlled Case Series; Hong Kong
Public URL https://nottingham-repository.worktribe.com/output/828534
Publisher URL http://www.nature.com/tp/journal/v6/n11/full/tp2016216a.html

Files





You might also like



Downloadable Citations